NCT07270874
Not yet recruiting
Phase 4
LIVER AKI: A Randomized, Open-label Trial to Evaluate the Efficacy of Intravenous Human Albumin Administration Versus Saline Solution (NaCl 0.9%) in Patients With descompénsate Cirrhosis and AKI 1B or Grater
Fundacion Clinic per a la Recerca Biomédica0 sites114 target enrollmentStarted: January 1, 2026Last updated:
InterventionsSaline solution (NaCl 0.9%)
Overview
- Phase
- Phase 4
- Status
- Not yet recruiting
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Enrollment
- 114
- Primary Endpoint
- probability of AKI resolution among patients with decompensated cirrhosis and AKI 1B or greater acute kidney injury (AKI) clinical efficacy of HA versus saline (NaCl 0.9%) administration in patients will be evaluated,
Overview
Brief Summary
This is a phase IV, unicentric, open-label. Patients eligible for this study will be patients with AKI 1B or greater and decompensated cirrhosis from the hospital participating in the study
Detailed Description
This is a phase IV, unicentric, open-label, randomized clinical trial to evaluate the efficacy of intravenous human albumin administration versus saline solution (NaCl 0.9%) in patients with decompensated cirrhosis and AKI 1B or grater.
Patients will be randomized to receive (1:1):
- Intravenous Human Albumin 20% (20 g/100 ml), at a dose of 1 g per kg body weight with a maximum of 100 g per day, during 48 hours.
- Saline solution (NaCl 0.9%) 500 ml every 24 hours, administered during 48 hours. Patients will be followed up for 28 days since the administration of the treatment (at baseline visit).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years old.
- •Cirrhosis defined by standard clinical criteria, ultrasonographic findings and/or histology. (Cirrhosis of any etiology may be included).
- •Patients with AKI 1B or greater, defined according to EASL guidelines (EASL. J Hepatol 2018).
- •Women of child-bearing potential\* must have a negative pregnancy test in serum before the inclusion in the study and agree to use highly effective contraceptive methods during the study. Highly effective contraceptive methods will include: intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence\*\* (only if refraining from heterosexual intercourse during the period of twelve months). Hormonal contraceptive methods will be avoided due to the risk of adverse events and impairment of liver function
Exclusion Criteria
- •Time since AKI diagnosis \> 24 hours.
- •Patients with AKI due to pure hypovolemia. According to guidelines, these patients should receive crystalloid solutions (i.e. NaCl 0.9%) and will be excluded from the study. Fluid losses will be specifically assessed by an accurate anamnesis and physical examination. If patient's diuretic treatment has been increased recently (within prior 2 weeks), or the patient had diarrhea before admission, patient will be considered that the AKI phenotype is pre-renal and will be excluded from the analysis. Patients will be excluded when clear evidence of hypovolemia is present, based on clinical history (e.g, recent fluid losses, diuretic escalation, diarrhea) and corroborating physical findings (e.g, dry mucous membranes, reduced skin turgor, sunken eyes, or low jugular venous pressure)
- •Patients with AKI due to gastrointestinal bleeding with AKI 1B or greater, and hemoglobin \< 7.0 g/dL. These patients can be included after 48 hours without rebleeding and Hb ≥ 8.0 g/dL, and still present AKI 1B or greater.
- •Patients who had already received albumin at the time of inclusion/exclusion criteria assessment.
- •Patients with Chronic kidney disease grade 3a or higher, defined as glomerular filtration rate \<60ml/min for three months and markers of kidney damage (one or more): Albuminuria (Albumin excretion rate \> 30 mg/24h; Albumin-to-creatinine ratio \> 30 mg/g), Urine sediment abnormalities, Electrolyte and other abnormalities due to tubular disorders, Abnormalities detected by histology or Structural abnormalities detected by imaging.
- •Patients under renal replacement therapy, or with urgent criteria of RRT.
- •Patients with hepatocellular carcinoma beyond Milan criteria.
- •Patients with severe extrahepatic comorbidities, including congestive heart failure New York Heart Association Grade III/IV, chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease group 2 or higher.
- •Previous liver and/or kidney transplantation.
- •Patients with current extra hepatic malignancies including solid tumors and hematologic disorders.
Arms & Interventions
Saline solution
Experimental
Saline solution (NaCl 0.9%) 500 ml every 24 hours, administered during 48 hours
Intervention: Saline solution (NaCl 0.9%) (Drug)
Outcomes
Primary Outcomes
probability of AKI resolution among patients with decompensated cirrhosis and AKI 1B or greater acute kidney injury (AKI) clinical efficacy of HA versus saline (NaCl 0.9%) administration in patients will be evaluated,
Time Frame: at any time during the study (all visits: screenning, basal , day 1, day2, day 5, day 7, day 15, and day 28)
defining AKI resolution as the proportion of patients with a decrease in serum creatinine levels \< 0.3 mg/dL with respect to baseline serum creatinine, without the need for TRT.
Secondary Outcomes
- Survival rate patients(at 28 days (visit 6))
- AKI improvement(basal visit , day 1, day2, day 5, day 7, day 15, and day 28))
- Proportion of patients requiring RRT In both groups(basal visit , day 1, day2, day 5, day 7, day 15, and day 28))
- Changes from baseline in systemic hemodynamics and vasoactive hormones: plasma renin concentration(basal visit , day 1, day2, day 5, day 7, day 15, and day 28))
- Changes in echocardiographic parameters (E/E', ITV, among others) at visit 1, 2, 7 and 28.(basal visit , day 1, day2, day 7, day, and day 28))
- Changes from baseline in systemic inflammatory response, evaluated by measurement in a large array of plasma cytokine levels (IL-6, IL8, IL-10, IL-1β)(basal visit , day 1, day2, day 5, day 7, day 15, and day 28))
- Proportion of patients and severity of treatment-related adverse events during the study period(screening visit,basal visit , day 1, day2, day 5, day 7, day 15, and day 28))
- Changes from baseline in systemic inflammatory response, evaluated by measurement in TNFα,(basal visit , day 1, day2, day 5, day 7, day 15, and day 28))
- Changes from baseline inG-CSF(basal visit , day 1, day2, day 5, day 7, day 15, and day 28))
- Changes from baseline in systemic hemodynamics and vasoactive hormones: plasma copeptin(basal visit , day 1, day2, day 5, day 7, day 15, and day 28),)
Investigators
Anna Cruceta
Clinical Research Manager
Fundacion Clinic per a la Recerca Biomédica
Similar Trials
Recruiting
Not Applicable
Using Hydroxychloroquine (HCQ) to Treat SteatohepatitisNCT07265297National Taiwan University Hospital210
Completed
Phase 1
Study in Participants With Normal Kidney Function and Reduced Kidney Function to Test How Kidney Function Can Change What Happens to Obeldesivir in the Body2023-504780-17-00Gilead Sciences Inc.10
Recruiting
Phase 1
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsNCT07262619Eikon Therapeutics160
Completed
Not Applicable
Bioequivalence Study Between YHP2406 and YHR2501 in Healthy SubjectsNCT07265167Yuhan Corporation63
Recruiting
Phase 2
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 TrialNCT07263438Centre Hospitalier Universitaire Vaudois59